Scotch Plains, NJ, United States of America

Feng Ye

This inventor holds 11 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 7 EPO patents. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2012-2025.

USPTO Granted Patents = 11 (Patent Applications = 4)

% Patents Active = 90.9

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 5)

Average Co-Inventor Count = 7.6

ph-index = 2

Forward Citations = 13(Granted Patents)

Company Filing History:

11 out of 2,405

Merck Sharp + Dohme Corp.

patents

Years Active: 2012-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12440496 - Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes (2025-10-14),

2. 12264134 - Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2025-04-01),

3. 11478461 - [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors (2022-10-25),

4. 11352320 - Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors (2022-06-07),

5. 10011572 - Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein (2018-07-03),

6. 9663534 - Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein (2017-05-30),

7. 9353101 - Cyclic amine substituted heterocyclic CETP inhibitors (2016-05-31),

8. 9346825 - Fused bicyclic oxazolidinone CETP inhibitor (2016-05-24),

9. 8871738 - Fused bicyclic oxazolidinone CETP inhibitor (2014-10-28),

10. 8742110 - Spiroxazolidinone compounds (2014-06-03),

11. 8304434 - Substituted aryl sulfone derivatives as calcium channel blockers (2012-11-06),

Title: The Inventor Spotlight: Feng Ye's Journey of Innovation

Introduction:

Meet Feng Ye, a prolific inventor hailing from Scotch Plains, NJ, who has made significant contributions to the field of pharmaceuticals and drug development. With a total of 9 patents under his belt, Feng Ye is a trailblazer in the world of inventors.

Latest Patents:

Among his latest patents is the groundbreaking work on bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors. These compounds, designed as inhibitors of the IDO enzyme, hold immense potential in the treatment and prevention of IDO-associated diseases and disorders. The compositions comprising these compounds open up new avenues for therapeutic interventions.

Career Highlights:

Feng Ye is a valued member of the Merck Sharp & Dohme Corporation, where his innovative spirit and dedication have led to the development of cutting-edge pharmaceutical solutions. His relentless pursuit of scientific excellence has garnered him recognition within the industry.

Collaborations:

Collaborating closely with esteemed colleagues such as Pengcheng Patrick Shao and Petr Vachal, Feng Ye has fostered a culture of teamwork and knowledge-sharing. Together, they have pushed the boundaries of pharmaceutical research, leading to groundbreaking discoveries and advancements in the field.

Conclusion:

In conclusion, Feng Ye's remarkable journey as an inventor showcases his unwavering commitment to driving innovation and making a lasting impact in the realm of drug development. His pioneering work on IDO inhibitors stands as a testament to his ingenuity and dedication to improving healthcare outcomes. Feng Ye's contributions resonate not only within Merck Sharp & Dohme Corporation but also reverberate across the broader scientific community, shaping the future of pharmaceutical advancements.